EngitixLondon-based Engitix Ltd has entered a strategic research collaboration and option agreement with GSK to discover and validate new therapeutic targets for liver fibrosis regression, adding another pharma partnership to its extracellular matrix-driven drug discovery platform.
ADVERTISEMENT